|
The novel indole-ether quinazoline AZD2171 is a highly potent (IC<sub>50</sub> < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
|
